Cerebrospinal Fluid and Clinical Profiles in Adult Type 2–3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience - Milella, Giammarco; Introna, Alessandro; D’Errico, Eustachio; Fraddosio, Angela; Scaglione, Gaspare; Morea, Antonella; Ucci, Maria; Ruggieri, Maddalena; Mastrapasqua, Mariangela; Megna, Marisa; Puntillo, Filomena; Simone, Isabella Laura (Clinical drug investigation, 2021)
Keywords: Adult; Age; Atrophy; Biomarkers; Cerebrospinal fluid; Creatinine; Cross-Sectional Studies; Diagnostic tests; Disease; Drug dosages; Humans; Internal Medicine; Medicine; Medicine & Public Health; Muscular Atrophy, Spinal - diagnosis; Muscular Atrophy, Spinal - drug therapy; Neurodegeneration; Neuromuscular diseases; Oligonucleotides; Original; Original Research Article; Pharmacology/Toxicology; Pharmacotherapy; Proteins; Spinal Muscular Atrophies of Childhood - diagnosis; Spinal Muscular Atrophies of Childhood - drug therapy; Italy